> ## Content Index
> Fetch the complete content index at: https://barna.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# Barcelona Leads EU Project on Affordable Cancer Therapy
- URL: https://barna.news/barcelona-leads-eu-project-on/
- Published: 2026-11-20T10:00:35.000Z
- Updated: 2026-11-20T10:00:35.000Z
- Description: A new Barcelona-coordinated European initiative aims to develop an off-the-shelf immunotherapy for multiple myeloma using stem cell-derived NK cells.
- Author: Barna.News News Desk
- Tags: Health

## Barcelona Coordinates €10M EU-Funded Cancer Research

The Banc de Sang i Teixits (BST) in Barcelona is leading a five-year European research project called iN-KEY, backed by nearly €10 million in Horizon Europe funding, to develop a faster, cheaper alternative to current CAR-T cancer immunotherapies. The initiative involves 12 partners across Europe, half of them Spanish, and focuses on creating an "off-the-shelf" treatment using Natural Killer (NK) cells derived from induced pluripotent stem cells sourced from umbilical cord blood. Unlike existing CAR-T therapies, which require modifying a patient’s own T cells and can cost around €300,000 per treatment, the proposed CAR-NK therapy could reduce costs to just 20% of that amount, according to Belén Álvarez-Palomo, BST researcher and project coordinator. Current treatments also take several weeks to produce, during which some patients deteriorate or become ineligible due to poor lymphocyte condition after chemotherapy.

## Focus on Multiple Myeloma with Future Expansion

The iN-KEY project will initially target multiple myeloma, the second most common blood cancer and one with limited curative options. In Spain, over 3,500 cases are diagnosed annually, with half occurring in people aged between 65 and 70\. Ageing demographics suggest rising incidence in coming years. NK cells offer two key advantages: they can be mass-produced from a single donor for use in multiple patients, and they carry a very low risk of graft-versus-host disease, making them safer than current cellular therapies. The genetic modification process will enable these cells to recognise and attack myeloma cells, with potential future application to other haematological and solid tumours.

## From Lab to Clinic in Five Years

The project officially began in October 2026 and will progress through laboratory engineering, scalable Good Manufacturing Practice (GMP)-compliant production, preclinical testing, and regulatory planning, culminating in a Phase 1 clinical trial involving 15 multiple myeloma patients at the Catalan Institute of Oncology (ICO). Yesterday, on Thursday 19th November 2026, BST hosted a meeting of all 12 consortium members, including Spanish institutions CSIC, CNIO, Avanther, Stab Therapeutics, and ICO-Idibell, alongside European partners CEA (France), Paul Ehrlich Institute (Germany), infrastructure provider EATRIS, and patient advocacy group Myeloma Patients Europe (Belgium).

> We need to take a step further so that it is just as effective as CAR-T, but more accessible and sustainable for healthcare systems, allowing us to reach many more patients. We believe that with NK cells produced from stem cells, we can achieve this.

Belén Álvarez, BST Coordinator and Principal Investigator The consortium aims to compress the traditional drug development timeline by integrating research, manufacturing, and regulatory processes from the outset. If successful, the therapy could enter clinical practice within a decade, pending trial outcomes and approval. Patients in Catalonia may eventually benefit from frozen CAR-NK cell batches stored for immediate use, with distribution planned at a European level.

---

*Sources:* [*La Vanguardia*](https://www.lavanguardia.com/vida/20261119/11688424/barcelona-lidera-desarrollo-inmunoterapia-cancer-barata-esperas.html?ref=barna.news)*,* [*bancsang.net*](https://www.bancsang.net/en/news/8648/the-banc-de-sang-i-teixits-bst-will-coordinate-a-pioneering-horizon-europe-project-against-cancer-using-natural-killer-nk-cells-together-with-12-european-partners?ref=barna.news)*.*

---

### Related on Barna.News

- [New RAS Inhibitors Offer Hope in Pancreatic Cancer](https://barna.news/new-ras-inhibitors-offer-hope-in/)
- [Catalan Paediatric Critical Care Network Launches](https://barna.news/catalan-paediatric-critical-care/)
- [10,000 Deaths Yearly in Catalonia Linked to Tobacco](https://barna.news/10-000-deaths-yearly-in-catalonia/)
- [Barcelona to Expand Thermal Bracelet Scheme for Outdoor Workers](https://barna.news/barcelona-to-expand-thermal-bracelet/)